Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion

Drugs, Jun 2016

R. Vellucci, G. Fanelli, P. A. Cortesi, R. Pannuti, C. Peruselli, P. Romualdi, Working Group Nientemale DEI

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs40265-016-0594-z.pdf

Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion

Drugs Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion Working Group Nientemale DEI 0 1 2 3 4 5 6 R. Vellucci 0 1 2 3 4 5 6 R. Pannuti 0 1 2 3 4 5 6 C. Peruselli 0 1 2 3 4 5 6 P. Romualdi 0 1 2 3 4 5 6 G. Fanelli 0 1 2 3 4 5 6 P. A. Cortesi 0 1 2 3 4 5 6 Dear Editor 0 1 2 3 4 5 6 0 SC Anestesia, Rianimazione e Terapia Antalgica, Azienda Ospedaliero-Universitaria di Parma , Parma , Italy 1 SOD Cure Palliative e Terapia del Dolore, Ospedale Universitario Careggi , Florence , Italy 2 & R. Vellucci 3 Dipartimento di Farmacia e Biotecnologie, Alma mater studiorum, Universita` di Bologna , Bologna , Italy 4 SC Cure Palliative, Ospedale di Biella , Ponderano, BI , Italy 5 Fondazione ANT Italia Onlus , Andria , Italy 6 Research Centre on Public Health (CESP), University of Milan-Bicocca , Monza , Italy - We would like to thank Raffaele Giusti and colleagues [ 1 ] for their comments on our paper [ 2 ]. Consistent with the motto ‘‘Actions speak louder than words’’, we have gathered a group of opinion leaders in palliative care and pain treatment who, for several years, have been committed to treat breakthrough cancer pain (BTcP). Our experience, gained by close contact with cancer pain sufferers, has allowed us to explore the literature on BTcP and to transfer it into clinical practice. We are convinced that the situation in Italy [ 3, 4 ], in Europe [5] and in other countries [ 6 ], is far from encouraging. In Italy, the phenomenon of under-treatment of cancer patients [ 7 ] and BTcP [ 3, 4, 8 ] is still an important problem. It must be made clear that rapid-onset opioids (ROOs) do not seem to be used very often in clinical practice [ 5, 8 ], as can be indirectly deduced from the Italian sales data. Specifically, about one-third of patients with BTcP did not receive any kind of rescue therapy, even in cases of patients with at least three attacks per day [8]. In terms of the drugs prescribed, one-third received a World Health Organization level I drug, while among the opioids, immediate-release (IR) morphine is significantly more frequently administered (71.2 %) than oral transmucosal fentanyl citrate (18.3 %) [ 8 ]. Even if IR morphine and fentanyl both act through the same mechanism of action, the route of administration influences the bioavailability of the drug, and the lipophilic future of fentanyl allows it to reach the brain very quickly. At first sight, IR morphine might appear to be less expensive, but it has a pharmacokinetic profile, which is inappropriate for most episodes of BTcP and becomes more efficacious than placebo after only 45 min, postbaseline [ 9 ]. That is not to say that morphine does not have a role in the treatment of BTcP, but rather that it may be useful in the management of breakthrough pain episodes lasting for more than 60 min, and may be considered in the preemptive management of volitional incident pain or procedural pain [ 10 ]. One fact seems unequivocal: missing or inappropriate treatment of BTcP results in an increase of BTcP-related office visits, emergency department visits, and hospitalizations [ 11–14 ], often with long hospital stays, and oncologic restaging, all of which have a significant impact on costs, much more relevant than the costs related to using ROOs in place of IR morphine. On the contrary, the correct utilisation of ROOs in clinical practice can reduce the burden of BTcP. Better analgesic efficacy can be translated into savings in health-care resources as well as an improved quality of life for patients [11]. Nevertheless, further studies are needed to better quantify the economic impact of BTcP and the benefits of using ROOs instead of IR morphine. We think that the long-term viability of our health-care system is closely linked to our clinical choices. We are fully aware that BTcP exacts a significant toll on patients, their families, caregivers, and social networks, the health-care system, and society at large. To lessen these effects, we have prepared a decalogue of ‘‘Five Things to Do and Five Things Not to Do’’ in the diagnosis and treatment of BTcP; but add that this is what we do every day with patients in clinical practice. We are convinced that this approach represents a solid basis for making the necessary progress for clinical management of BTcP, making our job easier. Furthermore, considering the variable approach on cancer pain management in the different Italian regions, depending on the environment and local resource availability, we considered it essential and more useful to share and discuss opinions between a consistent number of palliative care experts from all over the country and define some shared methods, rather than working on standard recommendations. In addition, we also paid close attention to communication with patients and their caregivers, an important issue often underestimated. An interesting issue needing (...truncated)


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs40265-016-0594-z.pdf

R. Vellucci, G. Fanelli, P. A. Cortesi, R. Pannuti, C. Peruselli, P. Romualdi, Working Group Nientemale DEI. Reply—Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion, Drugs, 2016, pp. 1063-1065, Volume 76, Issue 10, DOI: 10.1007/s40265-016-0594-z